RxDoctor Payments Data

Richard Lehrer, MD

Ophthalmology · Alliance, OHNPI 1477520393

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (57.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 23.4%. Reporting peaked in 2019 at $3,752 and has fallen 98.3% since, to $62 in 2025. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,636in general payments, 2019–2025

Across 198 payments — averaging $58.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$3K
  • Bausch & Lomb Americas Inc.$2K
  • Ivantis, Inc$1K
  • AbbVie$1K
  • Johnson & Johnson Surgical Vision, Inc.$1K
  • Alcon$670
  • plus $3K from 18 others
$94,832in research payments, 2019–2025

Across 65 payments — averaging $1458.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$95K

What the payments were for

  • Consulting fees$2,01617%
  • Speaking & faculty fees$2,00017%
  • Travel & lodging$5995%
  • Food & beverage$6,70158%
  • Education$2752%
  • Gifts$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,636 in reported general payments places this provider in the 90th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$36,934
Medicare patients
155
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost251$135,165
VyzultaLatanoprostene Bunod151$79,408
CombiganBrimonidine Tartrate/Timolol74$31,597
RhopressaNetarsudil Mesylate71$28,705
RestasisCyclosporine13$14,047
Alphagan PBrimonidine Tartrate30$10,987
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol63$10,958
RocklatanNetarsudil Mesylat/Latanoprost26$10,332
Travoprost44$8,827
Bimatoprost68$6,881
Prednisolone Acetate143$6,878
SimbrinzaBrinzolamide/Brimonidine Tart22$5,855
Brimonidine Tartrate266$5,789
Latanoprost385$4,668
Fluorometholone73$4,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$1,151$191,796368 claims
Bausch & Lomb Americas Inc.Vyzulta$2,270$79,408151 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$239$39,03897 claims
AlconSimbrinza$670$5,85522 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$570$2,10516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Alliance

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →